Viking Therapeutics Q4 2023 Earnings Report
Key Takeaways
Viking Therapeutics reported a net loss of $24.6 million, or $0.25 per share, for the fourth quarter ended December 31, 2023. The company's research and development expenses were $20.5 million, and general and administrative expenses were $8.8 million. As of December 31, 2023, Viking held approximately $362 million in cash, cash equivalents, and marketable securities.
Results for Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Expected in 1Q24
Histology Results for Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 1H24
Results for Phase 1 Trial of Oral VK2735 Expected in 1Q24
Strong Year-End Cash Position of $362 Million
Viking Therapeutics
Viking Therapeutics
Forward Guidance
Viking expects to report topline results from both the VENTURE Phase 2 study and the Phase 1 trial of oral VK2735 in the first quarter of 2024. The company expects to report the 52-week biopsy data from VOYAGE study in the first half of 2024.